Company Filing History:
Years Active: 2004-2006
Title: Dorothy Gallager: Innovator in GABA-Modulatory Compounds
Introduction
Dorothy Gallager is a notable inventor based in Columbus, MT (US). She has made significant contributions to the field of pharmacology, particularly in the development of methods for screening GABA-modulatory compounds. With a total of 2 patents, her work focuses on enhancing cognitive and emotional well-being through innovative scientific approaches.
Latest Patents
Gallager's latest patents include methods for screening GABA-modulatory compounds for specified pharmacological activities. These methods are designed to assay compounds for cognitive enhancing properties, anxiolytic properties, hypnotic properties, or antidepressant properties. The processes involve determining the in vitro efficacy and EC of the compounds at defined series of cloned GABA subtype receptors composed of specific variants of α, β, and γ subunits. This work aims to develop an activity profile for each compound. Additionally, the binding affinities of the compounds at GABA receptors may also be determined, and the in vivo effects of the compounds can be tested in animal models.
Career Highlights
Gallager is currently associated with Neurogen Corporation, where she applies her expertise in pharmacological research. Her innovative methods have the potential to significantly impact the treatment of various cognitive and emotional disorders.
Collaborations
Some of her notable coworkers include John Tallman and Kenneth Shaw, who contribute to the collaborative efforts in research and development at Neurogen Corporation.
Conclusion
Dorothy Gallager's work in the field of GABA-modulatory compounds showcases her dedication to advancing pharmacological science. Her innovative methods and collaborative spirit continue to pave the way for new therapeutic approaches.